Capt, while I don't disagree with you, I believe it is still going to be a LONG time before we see ANY revenue from most of these countries.
For perspective, Amarin inked a deal with HLS in Canada in 2017. Six years later, HLS recorded a grand total of $3.5M in gross revenue in Q1 2023 from sales of Vascepa.
Not to rain on anyone's parade, but I don't think Amarin is going to see ANY meaningful revenues outside the U.S. prior to a BO.
From my perspective, all of these agreements and approvals are simply teeing up a BO. So it is going to be up to the Board, et.al. to convince BP that Vascepa has a strong future for them.
And of course, we are all crossing our fingers for a blockbuster BRAVE readout. 🤞